People who have struggled with their weight have found relief with a new drug. But then their weight loss ground to a halt. A ...

MORGANTOWN – WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its ... of 24.4% over 48 weeks.

You might want to customize your Pwnagotchi to make it more personal. You can do this by changing the theme, adding plugins, or even creating your own plugins. If you ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

U.S.-listed shares of Ozempic and Wegovy maker Novo Nordisk (NVO) are jumping 14% in premarket trading after the Danish drugmaker reported positive Phase 1b/2a clinical trial ... of $4.74 billion ...